ZipLine Medical, Inc. has announced publication of positive results from two significant clinical studies in two peer-reviewed journals demonstrating that use of Zip® Surgical Skin Closure leads to better clinical outcomes and healthcare cost savings than do surgical staples.

A randomized, controlled, prospective study on patients undergoing same-day bilateral knee replacement conducted by Rodney Benner, MD, of the Shelbourne Knee Center in Indianapolis, Indiana, was published in the July online edition of the Journal of Knee Surgery. The study found that the Zip device provided statistically significant clinical and patient satisfaction benefits when compared to surgical staples. Patients demonstrated greater range of motion two weeks post-procedure during recovery and less pain on the knee closed with the Zip device compared to their stapled knee. In addition, patients, the surgeon and a blinded panel of plastic surgeons all preferred the scar quality on the Zip-closed knee.

“The Zip closure improved the patient experience, and as a result, I have changed my practice to include Zip closure in all knee arthroplasties,” said Dr. Benner. “Patients reported less pain, improved cosmetic outcomes, and even improved early function by improving range of motion.”

A separate health economics study of the Zip device conducted by Roger Emerson, MD, of the Texas Center for Joint Replacement, Plano, Texas, was recently published in the online journal Cureus. The study of 130 total knee replacement patients consisted of a retrospective chart review of patients receiving staple skin closure that was compared to a prospective case series of patients receiving the Zip device. Patients receiving staples had more incision- related phone calls to the clinic, incision-related ER admissions, incision-related clinic visits, and antibiotics prescribed due to incisional complications than the patients with Zip closure. The clinic cost for a problem staple patient was almost double that of the Zip group ($27 versus $14.75, respectively), while the opportunity cost for a problem staple patient was quadruple that of the Zip group ($228 versus $50, respectively.)

“The results of this study provide insight on how a simple change in the closure methodology can lead to potential downstream cost savings, especially in a bundled payment model,” said Dr. Emerson. “In the study, we noticed that patients were apprehensive about staple removal and concerned when they saw redness around their staples, which in some cases triggered antibiotic prescriptions to avoid possible infection.”

The Zip is a non-invasive and easy-to-use skin closure device that replaces sutures, staples and glue for surgical incisions and lacerations. A patented force distribution design results in secure wound closure, excellent scar quality and high patient satisfaction. Unlike staples or sutures, there are no skin punctures with the Zip that can create pathways for bacteria. Multiple clinical studies have demonstrated significant procedure time savings, fewer wound complications and the ability to reduce healthcare costs. Benefits of the Zip have been demonstrated in clinical studies in orthopedic total joint arthroplasty, spine, foot and ankle, pediatric cardiothoracic, electrophysiology, dermatology, emergency medicine and plastic and reconstructive surgery.

Latest news

VitalConnect Secures over $30 Million in Oversubscribed Series F Financing
July 18, 2023

SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed […]

CurvaFix Closes $39 Million Series C Financing Round Led by MVM Partners and Announces CEO Transition
July 14, 2023

BELLEVUE, Wash.–(BUSINESS WIRE)–CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the close of […]

Vertos Medical Secures $26 Million to Expand Commercialization Efforts and Develop Breakthrough Treatments for Chronic Low Back Pain
June 7, 2023

ALISO VIEJO, Calif., June 7, 2023 /PRNewswire/ — Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for […]

eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities
May 30, 2023

New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May […]

GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing
March 23, 2023

TEMPE, Ariz., March 23, 2023 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients […]

OSSIO Launches World’s First and Only Non-Permanent Compression Staple
February 7, 2023

OSSIOfiber® Compression Staple Answers Surgeon, Patient Demand in Fastest Growing Product Category in Extremities WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation […]

VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite
February 6, 2023

Second Generation GENOSYL® DS is the first and only Inhaled Nitric Oxide delivery system that is FDA-approved for rebreathing anesthesia, […]

VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
January 9, 2023

VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced […]

MVM Closes Oversubscribed Fund at $500 Million Hard Cap
November 14, 2022

BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]

MVM Invests in Ossio
October 18, 2022

Proceeds will be used to strengthen awareness for the patient benefits of bio-integrative OSSIOfiber® implants and accelerate new product platforms into the major […]